BioMed Research International / 2018 / Article / Tab 2

Research Article

CSF-S100B Is a Potential Candidate Biomarker for Neuromyelitis Optica Spectrum Disorders

Table 2

Discriminating value of CSF-GFAP and CSF-S100B levels for NMOSD, MS, OND, and NMOSD subgroups.

DiseasesBiomarkerAUCSensitivity ()Specificity ()Cut-off 95 CIp-Value

NMOSD vs MSS100B0.83971.491.7241.4 pg/ml0.74-0.94<0.001
GFAP0.85071.491.72.3 ng/ml0.75-0.95<0.001
NMOSD vs ONDS100B0.82365.3100.0300.2 pg/ml0.72-0.92<0.001
GFAP0.90767.3100.02.4 ng/ml0.83-0.98<0.001
MS vs ONDS100B0.45050.060.076.5 pg/ml0.12-0.660.661
GFAP0.66941.786.72.3 ng/ml0.11-0.140.137
Subgroups of NMOSD patients
AQP4 Ab+ vs MOG Ab+S100B0.86584.0100.0282.5 pg/ml0.74-0.990.002
GFAP0.77272.0100.06.2 ng/ml0.61-0.930.022
AQP4 Ab+ vs SeronegativeS100B0.58736.0100.02148.3 pg/ml0.41-0.760.350
GFAP0.64668.062.510.9 ng/ml0.48-0.810.118
MOG Ab+ vs SeronegativeS100B0.848100.081.2282.5 pg/ml0.68-1.000.006
GFAP0.613100.050.06.7 ng/ml0.39-0.840.375

AUC, area under curve; CI, confidence interval; CSF, cerebrospinal fluid; GFAP, glial fibrillary acidic protein; NMOSD, neuromyelitis optica spectrum disorder; MS, multiple sclerosis; OND, noninflammatory neurological diseases; AQP4 Ab+, aquaporin-4 antibody positive NMOSD; MOG-Ab+, myelin-oligodendrocyte glycoprotein antibody positive NMOSD.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.